688026.SH
洁特生物
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 15.54
−5.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 548.0M | 564.0M | 558.7M | 463.1M | 609.8M |
| Cost of Revenue | 330.6M | 330.5M | 327.3M | 321.3M | 415.6M |
| Gross Profit | 217.4M | 233.4M | 231.4M | 141.8M | 194.2M |
| Operating Expenses | |||||
| R&D Expense | 30.4M | 29.1M | 26.3M | 28.5M | 37.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 58.0M | 54.2M | 45.4M | 28.2M | 31.3M |
| Selling & Marketing Expense | 39.3M | 37.7M | 34.3M | 30.2M | 25.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 165.8M | 154.6M | 128.4M | 98.7M | 94.2M |
| Cost and Expenses | 496.4M | 485.1M | 455.7M | 420.0M | 509.8M |
| Operating Income (EBIT) | 38.7M | 62.4M | 95.7M | 39.4M | 96.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 37.2M | 60.9M | 95.6M | 38.3M | 98.0M |
| Income Tax Expense | 9.2M | 11.8M | 19.2M | 3.2M | 10.3M |
| Bottom Line | |||||
| Net Income | 27.6M | 48.2M | 75.6M | 34.8M | 87.7M |
| Earnings from Cont. Ops | 27.9M | 49.1M | 76.4M | 35.1M | 87.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 27.6M | 48.2M | 75.6M | 34.8M | 87.7M |
| Per Share | |||||
| Basic EPS | CN¥0.20 | CN¥0.35 | CN¥0.55 | CN¥0.25 | CN¥0.63 |
| Diluted EPS | CN¥0.20 | CN¥0.35 | CN¥0.55 | CN¥0.25 | CN¥0.63 |
| Revenue Per Share | CN¥3.89 | CN¥4.09 | CN¥4.06 | CN¥3.33 | CN¥4.38 |
| Shares | |||||
| Basic Shares Outstanding | 140.8M | 137.8M | 137.5M | 139.2M | 139.2M |
| Diluted Shares Outstanding | 140.8M | 137.8M | 137.5M | 139.2M | 139.2M |
| Profitability Metrics | |||||
| EBITDA | — | 116.4M | 156.7M | 97.9M | 149.9M |
| D&A | — | 54.1M | 61.0M | 58.5M | 53.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026